Vandetanib (ZD6474)
Drugonce daily oral dose
Other names: ZACTIMA™
NCT Number: NCT00494481
To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 2
Research Site, Budapest, Hungary
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
once daily oral dose
Other names: ZACTIMA™
intravenous infusion
Other names: Taxotere®
Time frame: RECIST tumour assessments carried out at screening (within 3 weeks before the 1st dose) and then as per site clinical practice until objective progression. The only additional mandatory RECIST assessment is at the point of data cut-off
Number of patients with objective disease progression or death (by any cause in the absence of objective progression)
Looking for future studies?
Notify MeGenzyme, a Sanofi Company
Industry
A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03455270
Adenocarcinoma, Advanced Breast Cancer
Beverly Hills, California, United States
View Trial DetailsNCT07829900
Advanced Breast Cancer, HER2-positive Breast Cancer
Nanjing, Jiangsu, China
View Trial DetailsNCT06047184
Advanced Breast Cancer
Changsha, Hunan, China
View Trial DetailsNCT06375707
Advanced Breast Cancer
Nanjing, Jiangsu, China
View Trial Details